ArticleScience translational medicine2019
Platelet decoys inhibit thrombosis and prevent metastatic tumor formation in preclinical models.
Article in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 81 citations in OpenAlex.
- Niches in cancer: from primary tumors to metastatic disease.Journal of hematology & oncology · 2026Review
- Review
- Platelet-Prostate cancer crosstalk driving disparities and therapeutic vulnerabilities.Discover oncology · 2026Review
- Soft cell-derived hybrid microparticles with platelet decoys for enhanced cancer chemotherapy.Acta pharmaceutica Sinica. B · 2026Article
- Engineering platelets as cancer therapeutics.Nature reviews. Clinical oncology · 2026Review
- From escort to target, the multidimensional roles and prospects of platelets in tumor immune checkpoint inhibitor therapy.Frontiers in immunology · 2026Review
- Phenotype independent capture of circulating tumor cell using magnetic platelet decoys.The journal of liquid biopsy · 2025Article
- Targeted codelivery of nitric oxide and hydrogen sulfide for enhanced antithrombosis efficacy.Bioactive materials · 2025Article
- Emerging Elastic Micro-Nano Materials for Diagnosis and Treatment of Thrombosis.Research (Washington, D.C.) · 2025Review
- Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. "Re-discovering the neglected biosources of the liquid biopsy family".The journal of liquid biopsy · 2024Review
- Advances in circulating tumor cells for early detection, prognosis and metastasis reduction in lung cancer.Frontiers in oncology · 2024Review
- The dynamic role of platelets in cancer progression and their therapeutic implications.Nature reviews. Cancer · 2024Review
- The prospects of microphysiological systems in modeling platelet pathophysiology in cancer.Platelets · 2023Review
- Tumor cell-induced platelet aggregation accelerates hematogenous metastasis of malignant melanoma by triggering macrophage recruitment.Journal of experimental & clinical cancer research : CR · 2023Article
- High Platelet Count is a Potential Prognostic Factor of the Early Recurrence of Hepatocellular Carcinoma in the Presence of Circulating Tumor Cells.Journal of hepatocellular carcinoma · 2023Article
- Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model.International journal of nanomedicine · 2023Article
- Upconversion nanoparticles regulated drug & gas dual-effective nanoplatform for the targeting cooperated therapy of thrombus and anticoagulation.Bioactive materials · 2022Article
- Nanoplateletsomes restrain metastatic tumor formation through decoy and active targeting in a preclinical mouse model.Acta pharmaceutica Sinica. B · 2022Article
- Beyond the thrombus: Platelet-inspired nanomedicine approaches in inflammation, immune response, and cancer.Journal of thrombosis and haemostasis : JTH · 2022Review
- Proteomic analysis of MSC-derived apoptotic vesicles identifies Fas inheritance to ameliorate haemophilia a via activating platelet functions.Journal of extracellular vesicles · 2022Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
Platelets are crucial for normal hemostasis; however, their hyperactivation also contributes to many potentially lethal pathologies including myocardial infarction, stroke, and cancer. We hypothesized that modified platelets lacking their aggregation and activation capacity could act as reversible inhibitors of platelet activation cascades. Here, we describe the development of detergent-extracted human modified platelets (platelet decoys) that retained platelet binding functions but were incapable of functional activation and aggregation. Platelet decoys inhibited aggregation and adhesion of platelets on thrombogenic surfaces in vitro, which could be immediately reversed by the addition of normal platelets; in vivo in a rabbit model, pretreatment with platelet decoys inhibited arterial injury-induced thromboembolism. Decoys also interfered with platelet-mediated human breast cancer cell aggregation, and their presence decreased cancer cell arrest and extravasation in a microfluidic human microvasculature on a chip. In a mouse model of metastasis, simultaneous injection of the platelet decoys with tumor cells inhibited metastatic tumor growth. Thus, our results suggest that platelet decoys might represent an effective strategy for obtaining antithrombotic and antimetastatic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.